The mode of action of thiazolidinediones

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue SUPPL. 2, 2002, Pages

  Hauner, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glitazones; Insulin resistance; Obesity; Peroxisome proliferator activated receptor gamma(PPAR ); Thiazolidinediones; Type 2 diabetes

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; FATTY ACID; FATTY ACID BINDING PROTEIN; FATTY ACID DERIVATIVE; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; INSULIN RECEPTOR; ISOPROTEIN; LIGAND; LIPID; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MALATE DEHYDROGENASE (DECARBOXYLATING); ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTANIC ACID; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN DERIVATIVE; PROSTANOID; PROTEIN KINASE C; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC OBESITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENERGY BALANCE; GENETIC CODE; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; LIVER TOXICITY; METABOLIC REGULATION; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; THIAZOLES; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036255529     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.249     Document Type: Article

References (59)

1. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus
2. Insulin resistance implications for type II diabetes mellitus and coronary heart disease
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
5. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
6. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling
7. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
8. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat
9. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
10. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes
11. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
12. Thiazolidinediones: A new class of antidiabetic drugs
13. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
14. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes
15. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome
16. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
17. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
18. Mechanisms by which thiazolidinediones enhance insulin action
19. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes
20. Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives
21. Preadipocyte differentiation in vitro: Identification of a highly active adipogenic agent
22. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
23. An antidiabetic thiazolidinedione has a high affinity for the nuclear peroxisome proliferator-activated receptorγ (PPARγ)
24. Peroxisome proliferator-activated receptor (PPAR)gamma: Adipose-predominant expression and induction early in adipocyte differentiation
25. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
26. Molecular regulation of adipogenesis
27. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα
28. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
29. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
30. Rosigitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots
31. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptorγ: Binding and activation correlate with antidiabetic actions in db/db mice
32. Peroxisome proliferator-activated receptors, orphans with ligands and functions
33. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology
34. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
35. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
36. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
37. Pristanic acid and phytanic acid: Naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha
38. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radio-iodinated ligand for peroxisomal proliferator-activated receptor gamma
39. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
40. PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPγ during the conversion of 3T3 fibroblasts into adipocytes
41. Troglitazone action is independent of adipose tissue
42. In vitro studies on the action of CS-045, a new antidiabetic agent
43. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats
44. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
45. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
46. Tumor necrosis factor α: A key component of the obesity-diabetes link
47. The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture
48. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells
49. Anti-diabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells
50. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-α: A potential new insulin-sensitizing mechanism for thiazolidinediones
51. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling
52. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes
53. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
54. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
55. Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus
56. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ
57. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects
58. Expression and function of PPARgamma in rat and human vascular smooth muscle cells
59. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD32 expression and HDL